Health and Healthcare

Pure Bioscience : PURE

PURE

Stock Data

$0.06

$0.00 (3.16%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

All Pure Bioscience Articles

5 Articles

Jon C. Ogg | Apr 7, 2010 at 1:25 PM EDT

BioHealth Business Daily (CELG, DUSA, ENCO, KERX, NPSP, OSIP, PFE, PURE, RNN, SQNM)

There are more recognized stocks in today’s edition of the BioHealth Business Daily. We are seeing significant and unusual moves,…

Jon C. Ogg | Apr 6, 2010 at 2:04 PM EDT

BioHealth Business Daily (RDEA, AVNR, CELG, DNDN, ENCO, OPXA, PURE, SVA)

Today’s wrap of the BioHealth Business Daily includes many less-covered stocks moving on news. We are seeing significant and unusual…

Douglas A. McIntyre | May 5, 2009 at 3:12 PM EDT

Speculative Swine Flu Stocks Make Last Stand (NVAX, GNBT, BCRX, PURE, VICL, VIVO, AVII)

It looks like everyone has figured out that swine flu was more of a media pandemic rather than a disease…

Douglas A. McIntyre | Apr 29, 2009 at 10:23 AM EDT

Speculative Swine Flu Stocks Giving It Back (NVAX, GNBT, BCRX, PURE, VICL, VIVO, AVII)

This week there have been many crazy stock gains among the speculative biotech sector, and these were tied directly to…

Douglas A. McIntyre | Apr 27, 2009 at 2:30 PM EDT

Flu Stock Index Continues Move Up (BRCX)(PURE)(NVAX)

The Tickerspy index of swine flu and bird flu stocks is up 21% as the market nears its close. The…

Pure Bioscience : PURE

PURE

$0.06

All Pure Bioscience Articles

BioHealth Business Daily (CELG, DUSA, ENCO, KERX, NPSP, OSIP, PFE, PURE, RNN, SQNM)

BioHealth Business Daily (RDEA, AVNR, CELG, DNDN, ENCO, OPXA, PURE, SVA)

Speculative Swine Flu Stocks Make Last Stand (NVAX, GNBT, BCRX, PURE, VICL, VIVO, AVII)

Speculative Swine Flu Stocks Giving It Back (NVAX, GNBT, BCRX, PURE, VICL, VIVO, AVII)

Flu Stock Index Continues Move Up (BRCX)(PURE)(NVAX)

COPX vs. CPER: Do Copper Miners or Copper Futures Best Play the Electrification Squeeze?

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

He Kept His Spouse’s Employer Plan Past 65. Medicare Called It a Gap — and Charged Him for Life.

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

He Kept His Spouse's Employer Plan Past 65. Medicare Called It a Gap — and Charged Him for Life.

COPX vs. CPER: Do Copper Miners or Copper Futures Best Play the Electrification Squeeze?

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

Pure Bioscience : PURE

PURE

$0.06

All Pure Bioscience Articles

BioHealth Business Daily (CELG, DUSA, ENCO, KERX, NPSP, OSIP, PFE, PURE, RNN, SQNM)

BioHealth Business Daily (RDEA, AVNR, CELG, DNDN, ENCO, OPXA, PURE, SVA)

Speculative Swine Flu Stocks Make Last Stand (NVAX, GNBT, BCRX, PURE, VICL, VIVO, AVII)

Speculative Swine Flu Stocks Giving It Back (NVAX, GNBT, BCRX, PURE, VICL, VIVO, AVII)

Flu Stock Index Continues Move Up (BRCX)(PURE)(NVAX)

COPX vs. CPER: Do Copper Miners or Copper Futures Best Play the Electrification Squeeze?

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

He Kept His Spouse’s Employer Plan Past 65. Medicare Called It a Gap — and Charged Him for Life.

Featured Reads

A Widow Turned Down the Survivor Check at 60 to Protect a Bigger One Later. The Wait Cost Her $50,000.

He Kept His Spouse's Employer Plan Past 65. Medicare Called It a Gap — and Charged Him for Life.